Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA Stok Raporu

Piyasa değeri: US$855.7m

Olema Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Sean Bohen

İcra Kurulu Başkanı

US$3.2m

Toplam tazminat

CEO maaş yüzdesi22.02%
CEO görev süresi6yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi1.2yrs
Yönetim Kurulu ortalama görev süresi6.1yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Sep 09

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27

Summary Olema Pharmaceuticals, Inc. is advancing palazestrant, a next-generation SERD, in two pivotal Phase 3 trials for ER+/HER2- metastatic breast cancer. Palazestrant claims best-in-class efficacy in both ESR1 mutant and wild-type tumors, but safety concerns, notably neutropenia, require validation in larger studies. Intense competition from multiple recently approved SERDs and delayed Phase 3 data (now Q1 2027) temper near-term upside for OLMA. I maintain a Hold rating on OLMA, as the current valuation reflects both potential and significant execution risks ahead of key catalysts. Read the full article on Seeking Alpha
Seeking Alpha • Apr 08

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Summary Olema Pharmaceuticals's palazestrant shows promise in late-stage trials for metastatic breast cancer, with potential FDA approval and commercial launch by 2027. Strong liquidity with $139.5 million in cash and $294.6 million in marketable securities, providing a cash runway of 4-4.5 years. Despite competition in the SERD space, OLMA's valuation is low at $200 million, suggesting potential for significant upside. The long-term outlook is positive, with OLMA positioned to deliver a reliable income-generating drug, making the current valuation a potential bargain. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Olema Pharmaceuticals: Interesting But Undifferentiated Data

Summary Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer, with promising early data in combination with ribociclib. Despite positive early-stage data, OLMA's phase 3 trial is open-label, making it difficult to position the molecule in a competitive market. Financially, OLMA has a solid cash runway of 11–18 quarters, but the ESR1+ mBC market is small with dominant existing players. I remain cautious about OLMA stock as an investment, awaiting more conclusive phase 3 data to better gauge its competitive positioning. Read the full article on Seeking Alpha
Seeking Alpha • Dec 02

Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward

Summary Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast cancer; Study to start mid-2025. Data from ongoing phase 3 OPERA-01 study, using palazestrant alone as a monotherapy to target patients with ER+/HER2- metastatic breast cancer, expected in 2026. The global breast cancer market size is predicted to surpass $89.01 billion by 2034. An IND Filing for KAT6 inhibitor OP-3136 to treat breast cancer patients is expected to happen in Q4 of 2024, with a phase 1 study being initiated in 2025. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 29

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jun 17

Olema Pharmaceuticals: Still Merits A Small Holding

Summary Olema Pharmaceuticals is focused on developing palazestrant and OP-3136 for women with cancer, with FDA Fast Track designation for palazestrant. Palazestrant is currently being evaluated in a Phase 3 clinical trial for ER+/HER2- advanced or metastatic breast cancer and as part of combination therapies. Analyst firms have reissued Buy ratings for Olema in June following trial updates, and the company's balance sheet is solid for now. An updated analysis around Olema Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • May 11

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 28

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Summary OLEMA Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted oncology therapies, with a focus on women's cancer. Their flagship drug, palazestrant, shows promising results for halting the progression of estrogen receptor-positive and HER2-negative breast cancer. The company has collaborations with Novartis and Pfizer and expects trial updates in 2024, but tangible FDA approvals and revenues are still a long way off. Despite promising developments, the long FDA approval and revenue generation timeline warrants a “hold” rating. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 04

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Key Insights Olema Pharmaceuticals' estimated fair value is US$14.37 based on 2 Stage Free Cash Flow to Equity Olema...
Analiz Makalesi • Nov 09

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Olema Pharmaceuticals...
Analiz Makalesi • Jun 11

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO Tazminat Analizi

Sean Bohen'un ücretlendirmesi Olema Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2026n/an/a

-US$205m

Mar 31 2026n/an/a

-US$185m

Dec 31 2025US$3mUS$700k

-US$162m

Sep 30 2025n/an/a

-US$150m

Jun 30 2025n/an/a

-US$142m

Mar 31 2025n/an/a

-US$129m

Dec 31 2024US$8mUS$673k

-US$129m

Sep 30 2024n/an/a

-US$123m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$99m

Dec 31 2023US$3mUS$647k

-US$97m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$97m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$6mUS$616k

-US$105m

Sep 30 2022n/an/a

-US$100m

Jun 30 2022n/an/a

-US$95m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$3mUS$595k

-US$71m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$11mUS$178k

-US$24m

Tazminat ve Piyasa: Sean 'ın toplam tazminatı ($USD 3.18M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.51M ).

Tazminat ve Kazançlar: Sean 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sean Bohen (59 yo)

6yrs
Görev süresi
US$3,178,990
Tazminat

Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President and also...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sean Bohen
President6yrsUS$3.18m0.27%
$ 2.3m
Shawnte Mitchell
Chief Legal Officer & Corporate Secretary1.6yrsUS$2.05m0%
$ 0
Jason O'Byrne
CFO, Principal Financial Officer & Accounting Officerless than a yearVeri yokVeri yok
David Myles
Chief Scientific Officerless than a yearUS$200.00k0.80%
$ 6.9m
Courtney O'Konek
Vice President of Corporate Communications2yrsVeri yokVeri yok
Julie Dexter
Senior VP & Head of Peopleno dataVeri yokVeri yok
Naseem Zojwalla
Chief Medical Officer4.7yrsUS$2.98m0.0051%
$ 43.9k
Richard Hernandez
Senior Vice President of Clinical Development Operations1.2yrsVeri yokVeri yok
Mark Shilkrut
Senior Vice President of Clinical Development1.2yrsVeri yokVeri yok
Kamesh Kuchimanchi
Senior Vice President of Regulatory Affairs & Quality Assurance1.2yrsVeri yokVeri yok
Angelos Dovletoglou
Senior Vice President of CMC & Supply Chain1.3yrsVeri yokVeri yok
Meghna Chowdary
Senior Vice President of Commercial Strategy & Operationsless than a yearVeri yokVeri yok
1.2yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş

Deneyimli Yönetim: OLMA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sean Bohen
President6yrsUS$3.18m0.27%
$ 2.3m
Andrew Rappaport
Independent Director13.7yrsUS$121.44k0.44%
$ 3.8m
Cynthia Butitta
Independent Director6.1yrsUS$126.84k0.096%
$ 820.3k
Ian T. Clark
Independent Chairperson of the Board6.1yrsUS$145.69k0%
$ 0
Frank McCormick
Chairman of Scientific Advisory Board5.4yrsUS$11.81kVeri yok
Pamela M. Klein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Sandra Horning
Independent Director5.8yrsUS$118.19k0%
$ 0
Scott Garland
Independent Director2.9yrsUS$119.39k0%
$ 0
Graham L. Walmsley
Independent Director6.5yrsUS$114.69k0%
$ 0
Yi Larson
Independent Director5.4yrsUS$125.91k0%
$ 0
Gorjan Hrustanovic
Independent Director8.2yrsUS$116.19k0%
$ 0
Cyrus Harmon
Independent Director20.1yrsUS$109.44k0.94%
$ 8.0m
6.1yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: OLMA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/09/16 00:01
Gün Sonu Hisse Fiyatı2026/09/16 00:00
Kazançlar2026/06/30
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Olema Pharmaceuticals, Inc. 18 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Arlinda LeeCanaccord Genuity
Naureen QuibriaCapital One Securities, Inc.
Zegbeh JallahCapital One Securities, Inc.